Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-20
2005-09-20
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S271000
Reexamination Certificate
active
06946482
ABSTRACT:
Motilide compounds having the formula (I),wherein R1, R2, R3, and R4are as defined herein, and methods for their preparation and use in the treatment of diseases or conditions characterized by impaired gastric motility.
REFERENCES:
patent: 4382085 (1983-05-01), Sciavolino et al.
patent: 4382086 (1983-05-01), Sciavolino et al.
patent: 4857641 (1989-08-01), Hauske et al.
patent: 4916138 (1990-04-01), Ueda et al.
patent: 5190871 (1993-03-01), Cox et al.
patent: 5288709 (1994-02-01), Freiberg et al.
patent: 5523401 (1996-06-01), Freiberg et al.
patent: 5523418 (1996-06-01), Freiberg et al.
patent: 5538961 (1996-07-01), Freiberg et al.
patent: 5554605 (1996-09-01), Freiberg et al.
patent: 5578579 (1996-11-01), Lartey et al.
patent: 5658888 (1997-08-01), Koga et al.
patent: 5712253 (1998-01-01), Lartey et al.
patent: 5824513 (1998-10-01), Katz et al.
patent: 5922849 (1999-07-01), Premchandran et al.
patent: 6066721 (2000-05-01), Khosla et al.
patent: 6077943 (2000-06-01), Omura et al.
patent: 6080555 (2000-06-01), Khosla et al.
patent: 6084079 (2000-07-01), Keyes et al.
patent: 6169168 (2001-01-01), Asaka et al.
patent: 6251636 (2001-06-01), Betlach et al.
patent: 6261816 (2001-07-01), Khosla et al.
patent: 6391594 (2002-05-01), Khosla et al.
patent: 6395710 (2002-05-01), Chu et al.
patent: 6403775 (2002-06-01), McDaniel
patent: 6437151 (2002-08-01), Leadlay et al.
patent: 6562795 (2003-05-01), Ashley et al.
patent: 2002/0004229 (2002-01-01), Santi et al.
patent: 2002/0094962 (2002-07-01), Ashley et al.
patent: 2002/0192709 (2002-12-01), Carreras et al.
patent: 2003/0220271 (2003-11-01), Ashley et al.
patent: 0119431 (1987-09-01), None
patent: 60-218321 (1985-11-01), None
patent: WO 99/21867 (1999-05-01), None
patent: WO 00/44717 (2000-08-01), None
patent: WO 01/27284 (2001-04-01), None
patent: WO 01/31035 (2001-05-01), None
patent: WO 01/83803 (2001-11-01), None
patent: WO 2004/013153 (2004-02-01), None
Pariza, RJ et al ‘Erythromycin: new chemistry on an old compound’ Pure & Appl. Chem., vol. 66 (10/11) 2365-2368 (1994).
Gordin, A et al ‘Concentrations of erythromycin, 2-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate’ Antimicrobial Agents&Chemotherapy, 1988, 1019-1024.
Carreras et al., “Saccharopolyspora erythraea-catalyzed bioconversion of 6-deoxyerythronolide B analogs for production of novel erythromycins,”J. Biotechnology, 92, 217-228 (2002).
Carreras et al., “Stable Expression of a Synthetic Gene for the Human Motilin Receptor: Use in an Aequorin-Based Receptor Activation Assay,”Anal. Biochem. 300, 146-15.
Frykman et al., “Precursor-Directed Production of Erythromycin Analogs bySaccharopolyspora erythraea,” Biotechnol. Bioeng., 76, 303-310 (2001).
Ku et al., “Synthesis and Antibacterial Activities of Novel 12-O-Methylerythromycin A Derivatives,”J. Antibiotics52(10), 908-912 (Oct. 1999).
Ku et al., “Synthesis of a Novel Macrolide: 9(S)-9-Dihydro-12-O-Methylerythromycin A via Regioselective Methylation,”J. Org. Chem., 64, 2107 (1999).
Omura et al., “Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationship,”J. Antibiotics(1985) 38: 1631-2.
Rodriguez et al.,J. Ind. Microbio. Biotechnol., “Rapid Engineering of Polyketide Overproduction by Gene Transfer to Industrially Optimized Strains,” web-published as document No. 10.1007/s10295-003-0045-1 (http://link.springer-ny.com) (Apr. 16, 2003).
Xue et al., “A Multiplasmid approach to preparing large libraries of polyketides,”Proc. Natl. Acad. Sci. U.S.A., 96, 11740-11745 (1999).
Chemical Abstracts No. 104:82047 (abstract of JP 60-218321).
Chemical Abstracts No. 130:325342 (abstract of WO 99/21867).
Chem. Abs. 90:152561 (abstract of PL 97877).
Hauske et al., “Regiospecific Synthesis of 9-Desoxoerythromycin A,”J. Org. Chem., 49, 712-714 (1984).
Hauske et al., “Aglycon Modifications of Erythromycin A: Regiospecific and Stereo-selective Elaboration of the C-12 Position,”J. Org. Chem., 52, 4622-4625 (1987).
Faghih et al., “Synthesis and Antibacterial Activity of (9S)-9-Dihydroclarithromycin,”J. Antibiotics, 43, 1334-1336 (1990).
Hauske et al., “Synthesis of 10,11-Anhydroerythromycin,”J. Org. Chem., 47, 1595-1596 (1982).
Hauske et al., “Aglycon Modifications of Erythromycin A and Erythromycin B: Regio-specific Nucleophilic Ring Opening of Cyclic Thionocarbonates,”J. Org. Chem., 48, 5138-5140 (1938).
Faghih et al., “Motilides and motilactides: design and development of motilin receptor agonists as a new class of gastrointestinal prokinetic drugs,”Drugs Fut., 23 (8), 861-872 (1998).
Depoortere et al., “Structure-Activity Relation of Erythromycin-Related Macrolides in Inducing Contractions and in Displacing Bound Motilin in Rabbit Duodenum,”J. Gastrointestinal Motility, 1, 150-159 (1989).
Faghih et al., “Preparation of 9-deoxo-4”-deoxy-6,9-epoxyerythromycin lactams “motilactides”: potent and orally active prokinetic agents,Bioorg. Med. Chem. Lett., 8, 805-810 (1998).
Carreras Christopher
Liu Yaoquan
McDaniel Robert
Metcalf Brian
Rodriguez Eduardo J.
Chao Yuan
Kosan Biosciences, Inc.
Owens Amelia A.
LandOfFree
Motilide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Motilide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Motilide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3444086